Cyclacel Pharmaceuticals Implements Reverse Stock Split

Introduction to CYCLACEL PHARMACEUTICALS INC

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company based in Berkeley Heights, New Jersey. The company utilizes insights from cell cycle biology, transcriptional regulation, epigenetics, and mitosis biology to develop oral drug candidates for oncology and hematology indications. Its ticker symbol is CYCC on the Nasdaq Capital Market, and trading data on July 2, 2025, showed a share price of $0.24, down 28.64 percent, on a volume of 1,883,341 shares.

Corporate Structure and Experience

Founded with a focus on leveraging cell cycle mechanisms to address therapeutic resistance, Cyclacel employs approximately 11–50 individuals. The leadership team includes Chief Executive Officer Datuk Dr. Doris Wong Sing Ee and President & CEO Spiro Rombotis, who participate in investor conferences and scientific symposia. The company retains worldwide rights to all pipeline candidates and is publicly reporting through SEC filings.

Biopharmaceuticals by little plant

Developments and News

• May 7, 2025: Cyclacel announced a 1-for-16 reverse stock split effective May 12, 2025, consolidating every 16 existing shares into one share without fractional issuance. The post-split share count is 22,272,346.
• June 3, 2025: Nasdaq’s Listing Qualifications Department confirmed that Cyclacel regained compliance with the minimum bid price requirement, maintaining its listing on the Nasdaq Capital Market.
• May 15, 2025: In its Q1 2025 financial report, Cyclacel announced a strategic focus on plogosertib (a PLK1 inhibitor), having repurchased related assets from its UK subsidiary for $0.3 million.
• October 2024: Enrollment completion in the Phase 2 study of Fadraciclib (CDK2/9 inhibitor) targeting patients with CDKN2A/B abnormalities was reported.
• September 9–11, 2024: Participation in the 26th Annual H.C. Wainwright & Co. Global Investment Conference, with presentations available on-demand.

Financial and Strategic Analysis

In Q1 2025, Cyclacel reported a net loss of $0.1 million, a reduction from a $2.9 million loss in Q1 2024. This result includes a one-time gain of approximately $5.0 million from deconsolidation of its UK subsidiary and reduced research-and-development expenses tied to the subsidiary’s liquidation. General and administrative expenses rose due to transaction-related costs. The company forecasts that its existing cash resources will support operations into the second quarter of 2025 and is evaluating strategic alternatives, including potential financing or mergers, to secure additional capital.

Market Position and Industry Context

Cyclacel operates in the oncology biotech sector where oral administration and mechanisms addressing therapy resistance are significant factors. Its two primary programs—Fadraciclib, a cyclin-dependent kinase 2/9 inhibitor, and Plogosertib, a polo-like kinase 1 inhibitor—target solid tumors and hematological malignancies. By concentrating on cell cycle control and epigenetic regulation, Cyclacel aims to expand treatment options in areas of high unmet medical need.

tl;dr

On May 12, 2025, Cyclacel implemented a 1-for-16 reverse stock split, resulting in a share count of 22.3 million. On June 3, 2025, the company regained Nasdaq minimum bid compliance. Q1 2025 results indicated a $0.1 million net loss, influenced by a deconsolidation gain and reduced R&D expenditure following the UK's subsidiary liquidation. Cyclacel’s cash runway extends into Q2 2025, and it is exploring financing or merger options while concentrating development efforts on plogosertib.